Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · June 06, 2023

Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Platinum-Resistant or Platinum-Refractory Ovarian Cancer

JAMA Oncology


Additional Info

JAMA Oncology
Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial
JAMA Oncol 2023 May 25;[EPub Ahead of Print], RW Holloway, AA Mendivil, JE Kendrick, LN Abaid, JV Brown, J LeBlanc, ND McKenzie, KM Mori, S Ahmad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading